From the MD&A Dated Feb 2021Research and Development Outlook Our R&D program for the 2021 fiscal year is anticipated to include: completion of patient enrollment, continuing to treat patients and obtain additional study data for the US Phase I/II clinical trial of our Cell Pouch System under our US IND at the University of Chicago for T1D patients with severe hypoglycemia in collaboration with JDRF; continuing production of human stem-cell-derived islet cells as a potential unlimited cell supply for ongoing in vivo safety and efficacy studies in preparation for future clinical evaluation within our Cell Pouch for the treatment of T1D; proceeding with a development plan to the clinic for our recently acquired Conformal Coating Technology augmented by the now licensed UMiami technology as a local immune protection technology for human donor islets and stem cell-derived technologies for Sernova’s clinical T1D therapeutics; completing the evaluation of AgeX’s UniverCyte local immune protection technology for our hemophilia and diabetes cell therapy applications; continuing to develop relationships towards potential collaborations with medical device (medtech) companies interested in Sernova’s regenerative medicine approach to the treatment of disease; executing R&D collaborations with pharmaceutical companies in support of a potential licensing arrangement and commercial development partnership of our combined technologies for our diabetes and other programs; and advancing our preclinical development programs towards human clinical evaluation for the treatment of postoperative hypothyroid disease and hemophilia A consisting of Cell Pouch transplanted therapeutic tissue / cells. I am posting this for those that are doing diligence, I suggest if you have questions you call Sernova...opposed to calling me names. Good luck